A Review on Advances in Personalized Medicine: from Genomics to Clinical Applications
Abstract
Keywords
Full Text:
PDFReferences
Shabaruddin, F. H., Fleeman, N. D., & Payne, K. (2015). Economic evaluations of personalized medicine: existing challenges and current developments. Pharmacogenomics and Personalized Medicine, 115-126.
Graig LA, Phillips JK, Moses HL, editors. Biomarker tests for molecularly targeted therapies: key to unlocking precision medicine. Washington, DC: National Academies Press; 2016.
Gupta S, Jhawat V. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems. J Control Release. 2017;245:15–26.
Hewitt, R. E. (2011). Biobanking: the foundation of personalized medicine. Current opinion in oncology, 23(1), 112-119.
Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., Kloczkowski, A. (2022). Innovations in genomics and big data analytics for personalized medicine and health care: A review. International journal of molecular Sciences, 23(9), 4645.
Ginsberg GS, Willard HF, editors. Genomic and Personalized Medicine. 2nd. London: Academic Press; 2013.
Alonso, S. G., de la Torre Díez, I., &Zapiraín, B. G. (2019). Predictive, personalized, preventive and participatory (4P) medicine applied to telemedicine and eHealth in the literature. Journal of medical systems, 43, 1-10.
Maayan, A., and Jenkins, S. L. Systems pharmacology meets predictive, preventive, personalized and participatory medicine. Pharmacogenomics 14(2):119–122, 2013.
Whirl‐Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F.,Klein, T.E. (2012). Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 92(4), 414-417.
Ehmann, F., Caneva, L., Prasad, K., Paulmichl, M., Maliepaard, M., Llerena, A., Papaluca-Amati, M. (2015). Pharmacogenomic information in drug labels: European Medicines Agency perspective. The pharmacogenomics journal, 15(3), 201-210.
Woodcock, J. (2007). The prospects for “personalized medicine” in drug development and drug therapy. Clinical Pharmacology & Therapeutics, 81(2), 164-169.
Guglielmo, A., Staropoli, N., Giancotti, M., & Mauro, M. (2018). Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations. Cost Effectiveness and Resource Allocation, 16(1), 1-14.
Hamburg, M. A., Collins, F. S. (2010). The path to personalized medicine. New England Journal of Medicine, 363(4), 301-304.
Collins FS, Morgan M, Patrinos A (2003). The Human Genome Project: lessons from large-scale biology. Science, 300, 286-290.
Hindorff LA, Bonham VL, Brody LC, et al.(2018). Prioritizing diversity in human genomics research. Nat Rev Genet. 19, 175-185. 16.Broeders M, Herrero-Hernandez P, Ernst MPT, van der Ploeg AT, Pijnappel WWMP. Sharpening the molecular scissors: advances in gene-editing technology. iScience. 23:100789-100789.
DOI: https://doi.org/10.37591/rrjodfdp.v10i2.1343
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production